Racotumomab

Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is an anti-idiotype monoclonal antibody (MAb). Racotumomab reacts to Neu-glycolyl (NeuGc)-containing gangliosides, sulfatides, and other antigens expressed in tumors. Racotumomab is an active anticancer agent for lung cancer[1][2][3].

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

Racotumomab induces a specific humoral and cellular immune response against the NeuGcGM3 ganglioside present in tumor cells, stimulating the cell death[4].

Racotumomab (50 μg/dose, i.p.) together with Keyhole limpet hemocyanin (KLH) inhibits tumor growth in F3II cell (s.c.) mammary tumor mice model[2]. Racotumomab (50 μg/dose, s.c.) together with Pemetrexed (100 mg/kg) is highly effective against lung nodules in 3LL cell (s.c.) mice xenograft[3]. Racotumomab (50-200 μg/dose, s.c.) shows no significant antitumor effect in 3LL cell (s.c.) mice xenograft[3]. Animal Model: 3LL cell (s.c.) mice xenograft[3] Dosage: 50 μg/dose, together with Pemetrexed (100 mg/kg) Administration: Subcutaneous injection (s.c.) Result: Reduced lung nodules.

[1]. Vázquez AM, et al. Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data. Front Oncol. 2012 Oct 23;2:150.  

[2]. Gajdosik Z. Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer. Drugs Today (Barc). 2014 Apr;50(4):301-7.  

[3]. Segatori VI, et al. Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Front Oncol. 2012 Nov 8;2:160.  

[4]. Truong CS, et al. Oncolytic Vaccinia Virus in Lung Cancer Vaccines. Vaccines (Basel). 2022 Feb 4;10(2):240.